The statin and ezetimibe combination continues to dominate the dyslipidemia treatment market. Prescriptions have more than tripled over the past 5 years, with the market size approaching nearly KRW 1 trillion. The rosuvastatin-ezetimibe combination drove market growth, posting more than KRW 600 billion in sales, while the atorvastatin-ezetimibe combination expanded more than threefold after the arrival of its generics. Prescriptions for pitavastatin-ezetimibe combinations also surged.

According to the market research institution UBIST, the outpatient prescription market for the statin-ezetimibe combinations totaled at KRW 990 billion ($90.9 million) last year. This is up 24.1% from the KRW 797.6 billion in